Clearside Biomedical, Inc.

Clearside Biomedical, Inc. is a clinical-stage ophthalmic biopharmaceutical company focused on developing therapies delivered into the suprachoroidal space of the eye. Its commercial product, XIPERE, is licensed to partners in the U.S., Canada and parts of Asia-Pacific, while the company’s internal development efforts are centered on CLS-AX and other eye-disease candidates using its SCS Microinjector platform.

−1 722,1 %

91,0 %

−2 064,4 %

−79,8 %

4.44

4.44

— Clearside Biomedical, Inc.
%
Commercial ophthalmic product20% XIPERE is the company’s approved therapy delivered into the suprachoroidal space for eye disease.
Drug delivery platform25% The SCS Microinjector platform enables targeted suprachoroidal administration of ophthalmic therapies.
License and collaboration revenue45% Upfront, milestone and royalty-based payments from partners using the platform or product rights.
Development pipeline10% CLS-AX and other proprietary ophthalmic candidates under preclinical and clinical development.

Clearside sells primarily to pharmaceutical and ophthalmology partners rather than to end patients directly...

  • Commercial licenseesprimary

    Partners such as Bausch + Lomb and Arctic Vision that commercialize XIPERE in licensed territories.

  • Development collaboratorsprimary

    Pharma and biotech companies that pay for access to the SCS Microinjector and related know-how.

  • Approved-product distributorssecondary

    Licensees that buy SCS Microinjector kits for use with approved ophthalmic products.

  • Future pipeline partnersemerging

    Potential partners for CLS-AX and other candidates if Clearside chooses to out-license development or commercialization.

Clearside is headquartered in the United States and its commercial footprint is shaped by partner territories rather...

  • •United States is the operating and financing center
  • •Canada is a licensed commercialization market for XIPERE
  • •Asia-Pacific, excluding Japan, is licensed to Arctic Vision
  • •Health Canada approval expands the Canadian market opportunity
  • •Geography is partner-driven, not direct-sales driven

Clearside’s near-term strategy is to preserve cash while advancing CLS-AX and other proprietary ophthalmic candidates...

01
Complete CLS-AX developmentshort-term

The company needs a successful late-stage asset to create future product revenue and reduce dependence on licensing income.

02
Expand platform partnershipsmedium-term

Additional collaborations can generate non-dilutive cash and validate the SCS Microinjector in more indications.

03
Secure financing and strategic flexibilityshort-term

The company has a limited cash runway and needs capital to continue development and avoid forced restructuring.

Clearside faces substantial going-concern and financing risk because it has recurring losses, negative operating cash...

critical

Going-concern and financing shortfall

The company expects to need additional capital to fund operations and complete CLS-AX development.

Scope
Cash burn, dilution, debt covenants or forced restructuring
Materiality
high
critical

Strategic alternative / liquidation risk

Management disclosed that failure to complete a strategic alternative could lead to bankruptcy, wind-down or dissolution.

Scope
Residual value for common shareholders
Materiality
high
high

Clinical and regulatory failure for CLS-AX

Pipeline value depends on successful development and approval of the lead candidate.

Scope
R&D spend and future product revenue
Materiality
high
high

Partner and licensing concentration

Revenue has historically come mainly from license agreements and collaboration payments.

Scope
XIPERE territories and future platform deals
Materiality
high
medium

Nasdaq delisting risk

Non-compliance with listing requirements could reduce liquidity and investor access.

Scope
Trading price and marketability of shares
Materiality
medium
License and collaboration revenue recognition
Can create lumpy quarterly revenue and non-cash revenue recognition
Royalty financing obligation
Affects interest expense and carrying value of the financing liability
Warrant fair value accounting
Can cause non-operating income statement volatility
Clinical trial accruals and R&D estimates
Can move research expense and operating loss timing

Axsome Therapeutics, Inc.

AXSM · Pharmaceutical Preparations

Xeris Biopharma Holdings, Inc.

XERS · Pharmaceutical Preparations

ClearPoint Neuro, Inc.

CLPT · Surgical & Medical Instruments & Apparatus

ARROWHEAD PHARMACEUTICALS, INC.

ARWR · Pharmaceutical Preparations

Milestone Pharmaceuticals Inc.

MIST · Pharmaceutical Preparations

X4 Pharmaceuticals, Inc

XFOR · Biological Products, (No Diagnostic Substances)

: 28/04/2026